Evidence map›Paper›PMID 42869994›Full record

ArticleNature medicine2026

Human-artificial intelligence collaboration for comanaging epilepsy in real time.

Zack Goldblum, Haoer Shi, Zhongchuan Xu, William K S Ojemann, Carlos A Aguila, Kevin Long, Kevin Xie, Kerry C Nix, Katherine G Walsh, Ellie Chang and 7 more

Abstract read
PubMed Publisher
In one paragraph

Article in Nature medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Zack Goldblum *Center for Neuroengineering and Therapeutics, University of Pennsylvania, Philadelphia, PA, USA. zackgold@engineering.upenn.edu.ORCID http://orcid.org/0000-0003-2803-7051
Haoer Shi *Center for Neuroengineering and Therapeutics, University of Pennsylvania, Philadelphia, PA, USA.ORCID http://orcid.org/0009-0000-5273-8371
Zhongchuan XuCenter for Neuroengineering and Therapeutics, University of Pennsylvania, Philadelphia, PA, USA.
William K S OjemannCenter for Neuroengineering and Therapeutics, University of Pennsylvania, Philadelphia, PA, USA.
Carlos A AguilaCenter for Neuroengineering and Therapeutics, University of Pennsylvania, Philadelphia, PA, USA.
Kevin LongPenn Medicine, University of Pennsylvania, Philadelphia, PA, USA.ORCID http://orcid.org/0000-0001-8881-2481
Kevin XieCenter for Neuroengineering and Therapeutics, University of Pennsylvania, Philadelphia, PA, USA.
Kerry C NixCenter for Neuroengineering and Therapeutics, University of Pennsylvania, Philadelphia, PA, USA.
Katherine G WalshCenter for Neuroengineering and Therapeutics, University of Pennsylvania, Philadelphia, PA, USA.
Ellie ChangCenter for Neuroengineering and Therapeutics, University of Pennsylvania, Philadelphia, PA, USA.
Sarah B LavelleCenter for Neuroengineering and Therapeutics, University of Pennsylvania, Philadelphia, PA, USA.
Brandon BachCenter for Neuroengineering and Therapeutics, University of Pennsylvania, Philadelphia, PA, USA.
Kathryn A DavisCenter for Neuroengineering and Therapeutics, University of Pennsylvania, Philadelphia, PA, USA.ORCID http://orcid.org/0000-0002-7020-6480
Nishant SinhaCenter for Neuroengineering and Therapeutics, University of Pennsylvania, Philadelphia, PA, USA.ORCID http://orcid.org/0000-0002-2090-4889
Lauren H HammerCenter for Neuroengineering and Therapeutics, University of Pennsylvania, Philadelphia, PA, USA.ORCID http://orcid.org/0000-0002-4045-490X
Erin C ConradCenter for Neuroengineering and Therapeutics, University of Pennsylvania, Philadelphia, PA, USA.
Brian LittCenter for Neuroengineering and Therapeutics, University of Pennsylvania, Philadelphia, PA, USA. littb@upenn.edu.ORCID http://orcid.org/0000-0003-2732-6927

Funding

Training Program in Neuroengineering and MedicineT32NS091006 · NINDS · UNIVERSITY OF PENNSYLVANIA · PI Brian Litt · 2015 to 2026
$4.1M
Scalable methods to quantify epileptic network and guide epilepsy surgeryK99NS138680 · NINDS · UNIVERSITY OF PENNSYLVANIA · PI SINHA, NISHANT · 2024 to 2025
$298k
U.S. Department of Defense (United States Department of Defense) W81XWH2210593U.S. Department of Health & Human Services | National Institutes of Health (NIH) DP1-NS-122038U.S. Department of Health & Human Services | National Institutes of Health (NIH) T32NS091006U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke (NINDS) K23 NS121401-01A1U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke (NINDS) K99NS138680U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke (NINDS) R01-NS-116504U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke (NINDS) R01-NS-125137U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke (NINDS) R61-NS-125568
6 · The paper itself

Abstract

One-third of the world's 70 million people with epilepsy have seizures uncontrolled by medication, and implantable devices are a promising treatment. These devices can detect impending seizures, missed medication and impaired cognition, but, like most medical devices, they cannot share this information with patients in real time. This is a missed opportunity for devices to learn from clinical events and teach patients how their behaviors affect their health. Here we present a device platform that converses with patients to help them manage their epilepsy. The inpatient prototype links scalp and intracranial electroencephalography (EEG) to a secure, large language model-based artificial intelligence (AI) that communicates bidirectionally through a smartphone app. The AI processes biomarkers of sleep, medication, cognition and seizure probability, notifies patients of clinical events and trends, records symptoms and responses, and uses their feedback to retrain its seizure detector, reducing false alarms. We validated this platform in 13 patients who are undergoing video-EEG monitoring for epilepsy (scalp, n = 11; intracranial, n = 2). In a pseudoprospective simulation, seizure detectors improved precision from patient feedback alone, without expert intervention. We propose this system as a scalable, safeguarded platform for medical devices that can rapidly adapt to patient and provider needs across epilepsy and other medical conditions.

Identifiers

PMID42869994

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.